Anti-IgE therapy: Clinical utility beyond asthma

Casale, Thomas B.; Stokes, Jeffrey R.

doi:10.1016/j.jaci.2009.02.016

Cited by 26 publications

(22 citation statements)

References 31 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conflicting data on the effectiveness may be due to the exceptionally high level of IgE in these patients making it difficult to reduce the levels to below 10 ng/ mL. 33 A recent trial in 7 pediatric patients with severe atopic dermatitis found that omalizumab was effective in reducing atopic dermatitis symptoms in a patient with a baseline IgE level as high as 17,190 IU/L. 34 The use of omalizumab in atopic dermatitis has been reported to reduce cytokines involved in T H 2 polarization.…”

Section: Atopic Dermatitismentioning

confidence: 99%

The Use of Anti-IgE Therapy Beyond Allergic Asthma

Stokes

Casale

2015

The Journal of Allergy and Clinical Immunology: In Practice

Self Cite

View full text Add to dashboard Cite

Section: Atopic Dermatitismentioning

confidence: 99%

The Use of Anti-IgE Therapy Beyond Allergic Asthma

Stokes

Casale

2015

The Journal of Allergy and Clinical Immunology: In Practice

Self Cite

View full text Add to dashboard Cite

“…Since omalizumab (anti-IgE) can be used to minimize adverse reactions during rush immunotherapy, it is possible that concomitant omalizumab and food SCIT can be used effectively [37].…”

Section: Subcutaneous Immunotherapymentioning

confidence: 99%

IgE-mediated food allergy

Calhoun

Schofield

2010

Current Opinion in Otolaryngology &Amp; Head &Amp; Neck Surgery

View full text Add to dashboard Cite

show abstract

“…In addition to being used for the treatment of asthma, omalizumab is also effective for the treatment of allergic rhinitis and atopic dermatitis. 1 The mechanisms by which omalizumab is effective in asthma treatment are not yet fully understood.…”

Section: Introductionmentioning

confidence: 99%

Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: A case report

Kao

Kuo

et al. 2012

Journal of Microbiology, Immunology and Infection

View full text Add to dashboard Cite

A skewed T-helper (T(h))1/T(h)2 immune response is considered to be the major cause of allergic disorders. Overproduction of T(h)2 cytokines, which promote recruitment and activation of mast cells and eosinophils, plays a key part in the pathogenesis of allergic asthma. The mechanisms by which omalizumab is effective in asthma treatment are not yet fully understood. A 16-year-old girl who was experiencing frequent asthma attacks in spite of daily administration of budesonide (640 μg) and montelukast (10mg) was given omalizumab (375 mg) at intervals of 2 weeks, to prevent a visit to the emergency room. Plasma levels of T(h)1 cytokines [interferon (IFN)-γ and interleukin (IL)-12p70], T(h)2 cytokines (IL-4 and IL-13), other proinflammatory and regulatory cytokines [IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β], chemokines [monocyte chemotactic protein (MCP)-1, chemokine ligand (CCL)7, and CCL17], and soluble Fas ligand (sFasL) were measured before treatment and after treatment for 8 weeks. She showed a good clinical response to omalizumab: her lung function parameters improved and the use of β2-agonist decreased. No emergency room visits were required after omalizumab treatment for 8 weeks. Plasma levels of sFasL and TGF-β showed obvious increases after omalizumab therapy. IL-12p70 levels were decreased as compared to the corresponding baseline levels. These findings suggest that the effects of omalizumab in asthma treatment are not restricted to the regulation of the skewed T(h)1/T(h)2 cytokine immune response, and sFasL-mediated apoptosis and regulatory T-cell (Treg)-mediated TGF-β seem to have important roles in the therapeutic effects of omalizumab.

show abstract

Anti-IgE therapy: Clinical utility beyond asthma

Cited by 26 publications

References 31 publications

The Use of Anti-IgE Therapy Beyond Allergic Asthma

The Use of Anti-IgE Therapy Beyond Allergic Asthma

IgE-mediated food allergy

Higher levels of soluble Fas ligand and transforming growth factor-β after omalizumab treatment: A case report

Contact Info

Product

Resources

About